Evaluation of EUCAST rapid antimicrobial susceptibility test directly from positive blood culture for Pseudomonas aeruginosa
In this study, we evaluated the performance of the EUCAST RAST method on a collection of 154 clinical strains of P. aeruginosa , including strains resistant to ceftazidime and carbapenems. While the test is convenient for routine laboratories, we observed significant rates of VME (ranging from 0.0 t...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical microbiology & infectious diseases 2024-10, Vol.43 (10), p.2061-2064 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2064 |
|---|---|
| container_issue | 10 |
| container_start_page | 2061 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 43 |
| creator | Lebreton, Cédric Fournier, Damien Jeannot, Katy |
| description | In this study, we evaluated the performance of the EUCAST RAST method on a collection of 154 clinical strains of
P. aeruginosa
, including strains resistant to ceftazidime and carbapenems. While the test is convenient for routine laboratories, we observed significant rates of VME (ranging from 0.0 to 15.0%) and ME (ranging from 1.3 to 16.3%) after 6 h, particularly for key antibiotics such as ceftazidime, piperacillin/tazobactam, and meropenem. Extending the incubation time to 8 h may improve results (CA ranging from 87.2 to 99%), but caution is required in interpretation due to persistence of VME (ranging from 0.0 to 15.6%) and ME (ranging from 0.0 to 11.7%). |
| doi_str_mv | 10.1007/s10096-024-04895-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3089513530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089513530</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-c94e957846d25613ad88644e46397c204fae4e461e0a168583ce3c6a8553d6523</originalsourceid><addsrcrecordid>eNp9kU1rHSEYhaU0NLdp_0AXReimm2l0XnV0GS63HxBooMlavI4TDM449SNwIT--JjdtoYtuFPE5x9dzEHpHySdKyHCe26pER3rWESYV7-QLtKEMeMdggJdoQxSwTg09nKLXOd-RJpLD8AqdgqKEK6E26GF3b0I1xccFxwnvbrYXP65xMqsfsVmKn71Nce9NwLlm69bi9z74csDF5YJHn5wt4YCnFGe8xuyLv3d4H2Icsa2h1OTwFBO-yq6OcY6Lydi4VG_9ErN5g04mE7J7-7yfoZvPu-vt1-7y-5dv24vLzgIhpbOKOcUHycTYc0HBjFIKxhwToAbbEzYZ93iijhgqJJdgHVhhJOcwCt7DGfp49F1T_Fnb4Hr27TMhmMXFmjWQlh4FDqShH_5B72JNS5tOQ8uMg2IDb1R_pFo4OSc36TX52aSDpkQ_dqOP3ejWjX7qRssmev9sXfezG_9IfpfRADgCuV0tty79ffs_tr8AZK6awQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3105539475</pqid></control><display><type>article</type><title>Evaluation of EUCAST rapid antimicrobial susceptibility test directly from positive blood culture for Pseudomonas aeruginosa</title><source>SpringerLink Journals</source><creator>Lebreton, Cédric ; Fournier, Damien ; Jeannot, Katy</creator><creatorcontrib>Lebreton, Cédric ; Fournier, Damien ; Jeannot, Katy</creatorcontrib><description>In this study, we evaluated the performance of the EUCAST RAST method on a collection of 154 clinical strains of
P. aeruginosa
, including strains resistant to ceftazidime and carbapenems. While the test is convenient for routine laboratories, we observed significant rates of VME (ranging from 0.0 to 15.0%) and ME (ranging from 1.3 to 16.3%) after 6 h, particularly for key antibiotics such as ceftazidime, piperacillin/tazobactam, and meropenem. Extending the incubation time to 8 h may improve results (CA ranging from 87.2 to 99%), but caution is required in interpretation due to persistence of VME (ranging from 0.0 to 15.6%) and ME (ranging from 0.0 to 11.7%).</description><identifier>ISSN: 0934-9723</identifier><identifier>ISSN: 1435-4373</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-024-04895-8</identifier><identifier>PMID: 39105969</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antibiotics ; Biomedical and Life Sciences ; Biomedicine ; Blood culture ; Brief Report ; Carbapenems ; Ceftazidime ; Drug resistance ; Infectious diseases ; Internal Medicine ; Medical Microbiology ; Meropenem ; Performance evaluation ; Piperacillin ; Pseudomonas aeruginosa ; Tazobactam</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2024-10, Vol.43 (10), p.2061-2064</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024</rights><rights>2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-c94e957846d25613ad88644e46397c204fae4e461e0a168583ce3c6a8553d6523</cites><orcidid>0000-0002-4634-8550</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10096-024-04895-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10096-024-04895-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39105969$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lebreton, Cédric</creatorcontrib><creatorcontrib>Fournier, Damien</creatorcontrib><creatorcontrib>Jeannot, Katy</creatorcontrib><title>Evaluation of EUCAST rapid antimicrobial susceptibility test directly from positive blood culture for Pseudomonas aeruginosa</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>In this study, we evaluated the performance of the EUCAST RAST method on a collection of 154 clinical strains of
P. aeruginosa
, including strains resistant to ceftazidime and carbapenems. While the test is convenient for routine laboratories, we observed significant rates of VME (ranging from 0.0 to 15.0%) and ME (ranging from 1.3 to 16.3%) after 6 h, particularly for key antibiotics such as ceftazidime, piperacillin/tazobactam, and meropenem. Extending the incubation time to 8 h may improve results (CA ranging from 87.2 to 99%), but caution is required in interpretation due to persistence of VME (ranging from 0.0 to 15.6%) and ME (ranging from 0.0 to 11.7%).</description><subject>Antibiotics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blood culture</subject><subject>Brief Report</subject><subject>Carbapenems</subject><subject>Ceftazidime</subject><subject>Drug resistance</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Medical Microbiology</subject><subject>Meropenem</subject><subject>Performance evaluation</subject><subject>Piperacillin</subject><subject>Pseudomonas aeruginosa</subject><subject>Tazobactam</subject><issn>0934-9723</issn><issn>1435-4373</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kU1rHSEYhaU0NLdp_0AXReimm2l0XnV0GS63HxBooMlavI4TDM449SNwIT--JjdtoYtuFPE5x9dzEHpHySdKyHCe26pER3rWESYV7-QLtKEMeMdggJdoQxSwTg09nKLXOd-RJpLD8AqdgqKEK6E26GF3b0I1xccFxwnvbrYXP65xMqsfsVmKn71Nce9NwLlm69bi9z74csDF5YJHn5wt4YCnFGe8xuyLv3d4H2Icsa2h1OTwFBO-yq6OcY6Lydi4VG_9ErN5g04mE7J7-7yfoZvPu-vt1-7y-5dv24vLzgIhpbOKOcUHycTYc0HBjFIKxhwToAbbEzYZ93iijhgqJJdgHVhhJOcwCt7DGfp49F1T_Fnb4Hr27TMhmMXFmjWQlh4FDqShH_5B72JNS5tOQ8uMg2IDb1R_pFo4OSc36TX52aSDpkQ_dqOP3ejWjX7qRssmev9sXfezG_9IfpfRADgCuV0tty79ffs_tr8AZK6awQ</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Lebreton, Cédric</creator><creator>Fournier, Damien</creator><creator>Jeannot, Katy</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4634-8550</orcidid></search><sort><creationdate>20241001</creationdate><title>Evaluation of EUCAST rapid antimicrobial susceptibility test directly from positive blood culture for Pseudomonas aeruginosa</title><author>Lebreton, Cédric ; Fournier, Damien ; Jeannot, Katy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-c94e957846d25613ad88644e46397c204fae4e461e0a168583ce3c6a8553d6523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibiotics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blood culture</topic><topic>Brief Report</topic><topic>Carbapenems</topic><topic>Ceftazidime</topic><topic>Drug resistance</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Medical Microbiology</topic><topic>Meropenem</topic><topic>Performance evaluation</topic><topic>Piperacillin</topic><topic>Pseudomonas aeruginosa</topic><topic>Tazobactam</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lebreton, Cédric</creatorcontrib><creatorcontrib>Fournier, Damien</creatorcontrib><creatorcontrib>Jeannot, Katy</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lebreton, Cédric</au><au>Fournier, Damien</au><au>Jeannot, Katy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of EUCAST rapid antimicrobial susceptibility test directly from positive blood culture for Pseudomonas aeruginosa</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>43</volume><issue>10</issue><spage>2061</spage><epage>2064</epage><pages>2061-2064</pages><issn>0934-9723</issn><issn>1435-4373</issn><eissn>1435-4373</eissn><abstract>In this study, we evaluated the performance of the EUCAST RAST method on a collection of 154 clinical strains of
P. aeruginosa
, including strains resistant to ceftazidime and carbapenems. While the test is convenient for routine laboratories, we observed significant rates of VME (ranging from 0.0 to 15.0%) and ME (ranging from 1.3 to 16.3%) after 6 h, particularly for key antibiotics such as ceftazidime, piperacillin/tazobactam, and meropenem. Extending the incubation time to 8 h may improve results (CA ranging from 87.2 to 99%), but caution is required in interpretation due to persistence of VME (ranging from 0.0 to 15.6%) and ME (ranging from 0.0 to 11.7%).</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>39105969</pmid><doi>10.1007/s10096-024-04895-8</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-4634-8550</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2024-10, Vol.43 (10), p.2061-2064 |
| issn | 0934-9723 1435-4373 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3089513530 |
| source | SpringerLink Journals |
| subjects | Antibiotics Biomedical and Life Sciences Biomedicine Blood culture Brief Report Carbapenems Ceftazidime Drug resistance Infectious diseases Internal Medicine Medical Microbiology Meropenem Performance evaluation Piperacillin Pseudomonas aeruginosa Tazobactam |
| title | Evaluation of EUCAST rapid antimicrobial susceptibility test directly from positive blood culture for Pseudomonas aeruginosa |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A33%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20EUCAST%20rapid%20antimicrobial%20susceptibility%20test%20directly%20from%20positive%20blood%20culture%20for%20Pseudomonas%20aeruginosa&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Lebreton,%20C%C3%A9dric&rft.date=2024-10-01&rft.volume=43&rft.issue=10&rft.spage=2061&rft.epage=2064&rft.pages=2061-2064&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-024-04895-8&rft_dat=%3Cproquest_cross%3E3089513530%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3105539475&rft_id=info:pmid/39105969&rfr_iscdi=true |